Literature DB >> 31401489

Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex.

Kazuki Oi1, Shuichiro Neshige2, Takefumi Hitomi3, Katsuya Kobayashi1, Maya Tojima1, Masao Matsuhashi4, Akihiro Shimotake4, Daiki Fujii5, Riki Matsumoto6, Shuhei Kasama7, Masutaro Kanda8, Yoshiaki Wada9, Hirofumi Maruyama10, Ryosuke Takahashi1, Akio Ikeda11.   

Abstract

OBJECTIVE: To elucidate the effects of perampanel (PER) on refractory cortical myoclonus for dose, etiology and somatosensory-evoked potential (SEP) findings.
METHODS: We examined 18 epilepsy patients with seizure and cortical myoclonus. Based on data accumulated before and after PER treatment, correlations among clinical scores in myoclonus and activities of daily life (ADL); early cortical components of SEP; and PER blood concentration, were analyzed.
RESULTS: PER (mean dose: 3.2 ± 2.1 mg/day) significantly improved seizures, myoclonus and ADL and significantly decreased the amplitude of and prolonged latency of giant SEP components. The degree of P25 and N33 prolongations (23.8 ± 1.6 to 24.7 ± 1.7 ms and 32.1 ± 4.0 to 33.7 ± 3.4 ms) were significantly correlated with improved ADL score (p = 0.019 and p = 0.025) and blood PER concentration (p = 0.011 and p = 0.025), respectively.
CONCLUSIONS: Low-dose PER markedly improved myoclonus and ADL in patients with refractory cortical myoclonus. Our results suggest that SEP, particularly P25 latency, can be used as a potential biomarker for assessing the objective effects of PER on intractable cortical myoclonus. SIGNIFICANCE: In this study, PER lessened the degree of synchronized discharges in the postsynaptic neurons in the primary motor cortex.
Copyright © 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Excitatory postsynaptic potential; Paroxysmal depolarization shift; Primary motor area; Progressive myoclonus epilepsy; Somatosensory-evoked potential

Mesh:

Substances:

Year:  2019        PMID: 31401489     DOI: 10.1016/j.clinph.2019.07.006

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  8 in total

Review 1.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

2.  Lance-Adams Syndrome Treated by Perampanel in the Acute Term.

Authors:  Masahito Katsuki; Norio Narita; Iori Yasuda; Teiji Tominaga
Journal:  Cureus       Date:  2021-03-08

3.  Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature.

Authors:  Giovanni Assenza; Cristofaro Nocerino; Mario Tombini; Giancarlo Di Gennaro; Alfredo D'Aniello; Alberto Verrotti; Alfonso Marrelli; Lorenzo Ricci; Jacopo Lanzone; Vincenzo Di Lazzaro; Leonilda Bilo; Antonietta Coppola
Journal:  Front Neurol       Date:  2021-03-24       Impact factor: 4.003

4.  Biodistribution and radiation dosimetry of the positron emission tomography probe for AMPA receptor, [11C]K-2, in healthy human subjects.

Authors:  Mai Hatano; Tomoyuki Miyazaki; Yoshinobu Ishiwata; Waki Nakajima; Tetsu Arisawa; Yoko Kuroki; Ayako Kobayashi; Yuuki Takada; Matsuyoshi Ogawa; Kazunori Kawamura; Ming-Rong Zhang; Makoto Higuchi; Masataka Taguri; Yasuyuki Kimura; Takuya Takahashi
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

5.  Replacement of Valproic Acid with New Anti-Seizure Medications in Idiopathic Generalized Epilepsy.

Authors:  Ayataka Fujimoto; Hideo Enoki; Keisuke Hatano; Keishiro Sato; Tohru Okanishi
Journal:  J Clin Med       Date:  2022-08-05       Impact factor: 4.964

6.  Perampanel improved intractable myoclonus in two patients with myoclonus epilepsy.

Authors:  Mutsumi Iijima; Hirokazu Oguni; Masaki Kobayashi; Kazuo Kitagawa
Journal:  eNeurologicalSci       Date:  2019-11-18

Review 7.  Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors.

Authors:  Takahisa Hanada
Journal:  Biomolecules       Date:  2020-03-18

8.  Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures.

Authors:  Eugen Trinka; Simona Lattanzi; Kate Carpenter; Tommaso Corradetti; Bruna Nucera; Fabrizio Rinaldi; Rohit Shankar; Francesco Brigo
Journal:  CNS Drugs       Date:  2021-07-07       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.